



Financial Statements
for the Fiscal Year Ended March 31, 2021
(From Apr. 1, 2020 to Mar. 31, 2021)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

May 12, 2021

Highlights in Business Results



(unit: JPY million)


	Apr. - Mar. 2020 Results	Apr. - Mar. 2021 Results	Diff.	Year-over-Year
Net sales	58,569	57,578	(990)	(1.7)%
Operating profit	2,314	2,127	(187)	(8.1)%
Ordinary profit	2,672	2,013	(658)	(24.6)%
Profit attributable to owners of parent	1,977	1,736	(241)	(12.2)%
Basic earnings per share	JPY 81.12	JPY 71.13	---	---
Exchange Rate (average during period)	US Dollar	108.74	106.06	Decreased in sales and profit.
	Euro	122.07	121.81	
	(unit: JPY) Singapore Dollar	79.28	77.65	

Sales	The impact of COVID-19 was refraining from doctor visits and postponing non-essential surgeries and procedures and the number of blood donations decreased		Profit	<ul style="list-style-type: none"> - Despite the decrease in sales expenses due to refrain from activities, the operating profit decreased due to increase in unit purchase prices of products in addition to the impact of the lower sales - The influence of equity losses of affiliated companies and foreign exchange losses, resulted in the decrease an ordinary profit
	Japan	<ul style="list-style-type: none"> - Increased sales of Closed Drug Mixing/Infusion System "NEO SHIELD" - Decreased sales of Infusion Sets 		
	Overseas	<ul style="list-style-type: none"> - Decreased sales of AV Fistula Needles and Apheresis kits for North America 	Dividend forecast	<ul style="list-style-type: none"> - Annual dividend: JPY 17 per share (incl. interim dividend JYP 8.5 per share)

Summary by segment (geographical area)

(unit: JPY million)

Japan




[Sales]

Increased sales of Hemodialysis Machines for China market and “NEO SHIELD” were offset by decreased sales of Infusion Sets, reducing net sales.

[Ordinary Income]

Despite the decreased selling cost, the influence of decreased sales and the increase in unit price of goods purchased resulted in a reduced profit.

Singapore




[Sales]

Decreased sales of AV Fistula Needle and Apheresis kits for North America market reduced net sales.

[Ordinary Income]

The influence of decreased sales and foreign exchange losses resulted in a reduced profit.

China



[Sales]

Increased sales of Blood Purification Tubing Sets and infusion/transfusion related products for the Japan market raised net sales.

[Ordinary Income]


The influence of increased sales due to addition of new products and other factors resulted in profit growth.

Summary by segment (geographical area)

(unit: JPY million)

Philippines

- Sales incl. internal transaction
- Sales for third party
- Profit



[Sales]


Increased sales of Apheresis kits for the North America market raised net sales.

[Ordinary Income]

The influence of expansion of sales and production resulted in profit growth.

Germany

- Sales incl. internal transaction
- Sales for third party
- Profit



[Sales]


Decreased sales of Blood bags reduced net sales.

[Ordinary Income]

The influence of foreign exchange losses resulted in a reduces profit.

Others

- Sales for third party
- Profit





*This segment includes business activity of subsidiaries in Japan, United States, South Korea and Thailand.


Sales by Business Segment

Apr. – Mar. 2020

Apr. – Mar. 2021




Sales change by Region (Customer's Location)



Selling, General and Admin. Expenses



(unit: JPY million)




(unit: JPY million)

	Apr. - Mar. 2020	Apr. - Mar. 2021	Diff.	Year-over-Year
Labor Cost	5,798	5,679	(119)	(2.1)%
Transport	1,715	1,750	35	2.0 %
R & D	1,417	1,600	183	12.9 %
Depreciation	352	337	(15)	(4.4)%
Others	4,039	3,600	(438)	(10.9)%
Total	13,323	12,968	(355)	(2.7)%

[Others] Travel expenses and advertising and promotion expenses decreased

Ordinary profit : Compared with the previous year



Forecast for FYE Mar. 2022



(unit: JPY million)

	FYE Mar. 2021 Result	FYE Mar. 2022 Forecast	Year-over-Year
Net sales	57,578	58,600	1.8%
Operating profit	2,127	2,100	(1.3)%
Ordinary profit	2,013	2,300	14.2%
Profit attributable to owners of parent	1,736	1,700	(2.1)%
Basic earnings per share	JPY 71.13	JPY 69.61	---

Exchange Rate (average during period)	US Dollar	106.06	108
	Euro	121.81	128
(unit: JPY)	Singapore Dollar	77.65	81

The forecast has been calculated based on the assumption that a certain the impact of COVID-19 will still remain in the subsequent consolidated fiscal years.

-Acquired the Acute Blood Purification Business from Japan Lifeline.
Feb. 2021

-Launched a new Enteral Nutrition Syringe Pump “EN-SP50”.
Mar. 2021



Enteral Nutrition Syringe Pump

-Development of a low dead space syringe.
Mar. 2021

Syringe
(upper: Conventional Products, lower: low dead space syringe)



View from the tip side

The tip's inner diameter has been reduced to reduce wasted space.

With integrated needle
(upper: Conventional Products, lower: long needle type)





The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.